EP1517702A4 - MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL - Google Patents

MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL

Info

Publication number
EP1517702A4
EP1517702A4 EP03709214A EP03709214A EP1517702A4 EP 1517702 A4 EP1517702 A4 EP 1517702A4 EP 03709214 A EP03709214 A EP 03709214A EP 03709214 A EP03709214 A EP 03709214A EP 1517702 A4 EP1517702 A4 EP 1517702A4
Authority
EP
European Patent Office
Prior art keywords
terminal cysteine
particles stabilized
hbc chimer
chimer particles
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03709214A
Other languages
English (en)
French (fr)
Other versions
EP1517702A2 (de
Inventor
Ashley J Birkett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/082,014 external-priority patent/US20030185858A1/en
Priority claimed from US10/080,299 external-priority patent/US20030175863A1/en
Priority claimed from US10/274,616 external-priority patent/US20030202982A1/en
Application filed by Apovia Inc filed Critical Apovia Inc
Publication of EP1517702A2 publication Critical patent/EP1517702A2/de
Publication of EP1517702A4 publication Critical patent/EP1517702A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP03709214A 2002-02-21 2003-02-21 MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL Withdrawn EP1517702A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/082,014 US20030185858A1 (en) 2001-08-15 2002-02-21 Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US80299 2002-02-21
US10/080,299 US20030175863A1 (en) 2001-08-15 2002-02-21 Influenza immunogen and vaccine
US82014 2002-02-21
US10/274,616 US20030202982A1 (en) 2001-08-15 2002-10-21 Influenza immunogen and vaccine
US274616 2002-10-21
PCT/US2003/005196 WO2003102165A2 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Publications (2)

Publication Number Publication Date
EP1517702A2 EP1517702A2 (de) 2005-03-30
EP1517702A4 true EP1517702A4 (de) 2006-05-03

Family

ID=29715970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03709214A Withdrawn EP1517702A4 (de) 2002-02-21 2003-02-21 MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL

Country Status (3)

Country Link
EP (1) EP1517702A4 (de)
AU (1) AU2003213168A1 (de)
WO (1) WO2003102165A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
AU2007297801A1 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2069483A4 (de) 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co Rekombinante rhinovirus-vektoren
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CN106279379B (zh) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 一种免疫原HM4-M2e及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO1999057289A2 (en) * 1998-05-04 1999-11-11 Michigan State University INHIBIN-HBc FUSION PROTEIN
WO2002014478A2 (en) * 2000-08-16 2002-02-21 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO1999057289A2 (en) * 1998-05-04 1999-11-11 Michigan State University INHIBIN-HBc FUSION PROTEIN
WO2002014478A2 (en) * 2000-08-16 2002-02-21 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KRATZ P A ET AL: "NATIVE DISPLAY OF COMPLETE FOREIGN PROTEIN DOMAINS ON THE SURFACE OF HEPATITIS B VIRUS CAPSIDS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 96, 1999, pages 1915 - 1920, XP000910194, ISSN: 0027-8424 *
SEIFER M ET AL: "Stability governs the apparent expression of particulate hepatitis e antigen by mutant hepatitis B virus core particles", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 196, no. 1, September 1993 (1993-09-01), pages 70 - 78, XP002961918, ISSN: 0042-6822 *
ULRICH R ET AL: "CORE PARTICLES OF HEPATITIS B VIRUS AS CARRIER FOR FOREIGN EPITOPES", ADVANCES IN VIRUS RESEARCH, SAN DIEGO, CA, US, vol. 50, 1998, pages 141 - 182, XP000856161 *
ZHOU S ET AL: "Cys residues of the hepatitis B virus capsid protein are not essential for the assembly of viral core particles but can influence their stability", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 9, September 1992 (1992-09-01), pages 5393 - 5398, XP002961917, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2003102165A2 (en) 2003-12-11
AU2003213168A1 (en) 2003-12-19
AU2003213168A8 (en) 2003-12-19
WO2003102165A3 (en) 2005-01-06
EP1517702A2 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
EP1492049A4 (de) Erzeugung von gesichts-metadaten
HRP20041200A2 (en) Acidic insulin preparations with improved stability
IL172059A0 (en) Stabilized radiopharmaceutical compositions and methods for the preparation thereof
AU2003243715A1 (en) Thermal interface materials
EP1578930A4 (de) Cngh0004-polypeptide, antikörper, zusammensetzungen, verfahren und verwendungen
GB2419421B (en) Gas flow standard
AU2003225901A8 (en) Stabilized inorganic particles
GB2392424B (en) Fuel sender assembly
AU2003213168A8 (en) Immunogenic hbc chimer particles stabilized with an n-terminal cysteine
AU2003206862A1 (en) Hepatitis b vaccines
GB2390234B (en) Fuel sender assembly
AU2003215395A8 (en) Stabilized hbc chimer particles having meningoccocal immunogens
AU2003254483A8 (en) Fuel composition
IL168106A0 (en) Stabilized, solid-state polypeptide particles
TW547897U (en) Housing with separated carrying seat
AU2003303222A8 (en) Mutant proteins with increased secretion
EP1539792A4 (de) Cngh0005-polypeptide, antikörper, zusammensetzungen, verfahren und verwendungen
AU2003249282A1 (en) Glanders/meliodosis vaccines
IL172802A0 (en) Aztreonam l-lysine and methods for the preparation thereof
GB0201382D0 (en) Virus-like particles
PL372202A1 (en) Modified byrodin 1 with reduced immunogenicity
GB0208414D0 (en) The overlock
AU2003213194A8 (en) Immunogenic avian hbc chimer particles having enhanced stability
TW560628U (en) Improved carbon powder bottle
HK1078255A (en) Propofol with cysteine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040921

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20060320

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/385 20060101ALI20060315BHEP

Ipc: A61K 39/29 20060101ALI20060315BHEP

Ipc: C12Q 1/70 20060101AFI20060315BHEP

17Q First examination report despatched

Effective date: 20091130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130216